3.0
Jul 1, 2026
Cytiva’s operating model needs stronger governance and more reliable execution.
Anonymous employee
Current employee, more than 3 years
Recommend
CEO approval
Business Outlook
Pros
Strong mission and meaningful work in life science and solid benefits.
Cons
Cytiva’s governance remains structurally weak, with unclear decision rights, inconsistent leadership alignment, and frequent restructuring that disrupts accountability. Many leaders have no pharmaceutical background, which creates oversimplified assumptions about customs‑heavy, GMP‑linked operations. The organisation still carries legacy cowboy behaviours from the Pall/GE era—fast moves, RACI ambiguity, low discipline in decision‑making, and direction that shifts without a stable architectural backbone. DBS often overshadows quality systems, prioritising tool cadence over regulatory depth, further amplifying structural instability.
